9/13/2013

Cubist Pharmaceuticals has finalized its purchase of antibiotics-maker Trius Therapeutics for about $704 million. The deal will give Cubist access to Trius' tedizolid phosphate, a late-stage antibiotic under development for certain Gram-positive infections, as well as antibiotics programs that have yet to reach human studies.

Related Summaries